Plant Name: Gypsophila licentiana hand.-mazz.
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.346E-09 | 4.543E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.611E-08 | 6.434E-05 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.765E-07 | 3.494E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.494E-06 | 5.696E-03 | CYP1A2, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 7.140E-06 | 6.653E-03 | CA2, CYP1A2, FABP5, HTT, LMNA, POLB, PPARA, PPARD, SMN1, SMN2, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0070482; response to oxygen levels | 7.333E-06 | 6.653E-03 | LMNA, POLB, PPARA, PPARD, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006631; fatty acid metabolic process | 7.965E-06 | 6.937E-03 | CYP1A2, CYP2C19, FABP3, PPARA, PPARD |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.115E-05 | 8.996E-03 | CYP1A2, CYP2C19, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.535E-11 | 2.121E-09 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.615E-06 | 7.844E-05 | CYP1A2; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.660E-05 | 7.321E-04 | CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.139E-05 | 9.208E-04 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.277E-03 | 1.369E-02 | FABP4; TSHR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.369E-03 | 1.369E-02 | CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.716E-03 | 1.439E-02 | CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.159E-03 | 1.439E-02 | CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.043E-03 | 1.439E-02 | CA2; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.741E-03 | 2.845E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| NA: NA | Dyslipidemia | NA | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TLR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |